Medicus Pharma Ltd (NASDAQ:MDCX) Stock Has Average Price Target of $450.00

Medicus Pharma Ltd (NASDAQ:MDCX) has been assigned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $450.00.

A number of equities analysts have recently issued reports on the company. Weiss Ratings raised Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Brookline Capital Markets lowered Medicus Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Finally, Wall Street Zen downgraded shares of Medicus Pharma from a “sell” rating to a “strong sell” rating in a research note on Sunday.

Medicus Pharma Trading Down 7.2%

MDCX stock traded down $0.13 during midday trading on Wednesday, hitting $1.70. The stock had a trading volume of 39,550 shares, compared to its average volume of 82,497. Medicus Pharma has a 52 week low of $1.68 and a 52 week high of $127.50. The stock has a 50-day simple moving average of $5.69 and a 200 day simple moving average of $21.07. The firm has a market capitalization of $2.14 million, a price-to-earnings ratio of -0.02 and a beta of 0.80.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Friday, November 6th. The company reported ($11.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.50) by ($3.14). On average, equities analysts forecast that Medicus Pharma will post -33.50 EPS for the current year.

Institutional Trading of Medicus Pharma

Several hedge funds have recently modified their holdings of MDCX. Interchange Capital Partners LLC boosted its holdings in shares of Medicus Pharma by 33.9% in the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after acquiring an additional 538,039 shares in the last quarter. Private Advisor Group LLC increased its holdings in Medicus Pharma by 36.8% during the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after purchasing an additional 64,560 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. bought a new position in Medicus Pharma in the 2nd quarter valued at $45,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes. Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.